Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers with obesity
· Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation · Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated Lund, Sweden — 24 June 2020 — Camurus’ partner Rhythm Pharmaceuticals, Inc. today announced interim data from a Phase 2 study evaluating once-weekly setmelanotide, CAM4072, an investigational melanocortin-4 receptor (MC4R) agonist. Healthy people with obesity treated with the weekly formulation of setmelanotide achieved comparable weight loss to those treated with the daily